(Q58971166)
Statements
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD (English)
Stanley B Cohen
E Michael Lewiecki
Paul D Miller
Michael A Bolognese
Yu Liu
Andrea Wang
Suresh Siddhanti
Lorraine A Fitzpatrick
AMG 162 Bone Loss Study Group
1 reference